Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.32 -0.5%	$8.94	$6.38 ▼ $17.30	$906.44M	1.45	1.27 million shs	1.27 million shs
ESPR Esperion Therapeutics	$1.10 +0.9%	$0.96	$0.69 ▼ $3.94	$216.04M	0.67	5.25 million shs	2.52 million shs
NRIX Nurix Therapeutics	$11.62 +2.0%	$10.75	$8.18 ▼ $29.56	$868.32M	2.15	863,306 shs	491,613 shs
PRAX Praxis Precision Medicines	$42.97 -1.1%	$38.04	$26.70 ▼ $91.83	$885.24M	2.6	387,076 shs	254,896 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.53%	-5.76%	-0.32%	+7.50%	-40.26%
ESPR Esperion Therapeutics	+0.92%	-9.09%	+27.33%	-32.10%	-59.56%
NRIX Nurix Therapeutics	+2.02%	-8.00%	+22.19%	-16.22%	-36.98%
PRAX Praxis Precision Medicines	-1.13%	-3.65%	+15.05%	+14.01%	+14.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.218 of 5 stars	3.5	1.0	0.0	2.7	1.7	0.6
ESPR Esperion Therapeutics	4.1555 of 5 stars	3.3	3.0	3.9	3.2	1.7	0.6
NRIX Nurix Therapeutics	1.3566 of 5 stars	3.4	1.0	0.0	1.7	0.8	0.0
PRAX Praxis Precision Medicines	2.9448 of 5 stars	4.4	2.0	0.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	94.92% Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	468.18% Upside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	159.69% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$109.90	155.76% Upside

Current Analyst Ratings Breakdown

Latest ESPR, AVDL, NRIX, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/5/2025	PRAX Praxis Precision Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$26.00 ➝ $28.00
5/5/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/1/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	5.33	N/A	N/A	$0.77 per share	12.10
ESPR Esperion Therapeutics	$332.31M	0.66	$0.02 per share	45.37	($1.97) per share	-0.56
NRIX Nurix Therapeutics	$54.55M	16.24	N/A	N/A	$7.44 per share	1.56
PRAX Praxis Precision Medicines	$8.55M	102.37	N/A	N/A	$23.90 per share	1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	155.33	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)

Latest ESPR, AVDL, NRIX, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
ESPR Esperion Therapeutics	N/A	1.18	0.81
NRIX Nurix Therapeutics	N/A	6.26	6.26
PRAX Praxis Precision Medicines	N/A	8.44	8.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
ESPR Esperion Therapeutics	47.39%
NRIX Nurix Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
ESPR Esperion Therapeutics	1.70%
NRIX Nurix Therapeutics	7.40%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	92.10 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable

ESPR, AVDL, NRIX, and PRAX Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Sells 51,682 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

June 14, 2025 | marketbeat.com

Needham & Company LLC Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)

June 12, 2025 | marketbeat.com

Bank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

June 12, 2025 | marketbeat.com

Former head trader of Denver-based investing company pleads guilty to insider trading

June 9, 2025 | finance.yahoo.com

Weston man pleads guilty to insider trading offense that made him $220K

June 8, 2025 | stamfordadvocate.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 7.6% - Here's Why

June 5, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 4, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLP

June 4, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLC

June 4, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

June 3, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at Oppenheimer

June 2, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial Markets

June 1, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 5.6% - Should You Sell?

May 31, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading 4.3% Higher - Should You Buy?

May 30, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

May 28, 2025 | marketbeat.com

9,948 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Purchased by Woodline Partners LP

May 28, 2025 | marketbeat.com

Voloridge Investment Management LLC Buys 40,875 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

May 27, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Millennium Management LLC

May 26, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Boosted by VR Adviser LLC

May 22, 2025 | marketbeat.com

Velan Capital Investment Management LP Sells 50,666 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

May 21, 2025 | marketbeat.com

Soleus Capital Management L.P. Sells 15,858 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, AVDL, NRIX, and PRAX Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.32 -0.05 (-0.53%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.32 0.00 (0.00%)

As of 06/18/2025 04:33 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Esperion Therapeutics NASDAQ:ESPR

$1.10 +0.01 (+0.92%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.02 (+1.82%)

As of 06/18/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Nurix Therapeutics NASDAQ:NRIX

$11.62 +0.23 (+2.02%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.62 +0.01 (+0.04%)

As of 06/18/2025 04:39 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$42.97 -0.49 (-1.13%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$42.98 +0.02 (+0.03%)

As of 06/18/2025 05:08 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time